Moderna, Inc. (NASDAQ:MRNA) is expected to report third quarter earnings results, before market open, on Thursday 29th October 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.43 per share.
Looking ahead, the full year loss are expected at $ 1.46 per share on the revenues of $ 309.22 million.
Previous Quarter Performance
Moderna, Inc. unwinded loss for the second quarter of $ 0.31 per share, from the revenue of $ 66.35 million. The quarterly revenues swell 407.26 percent compared with the same quarter last year. Wall street analysts are predicting, MRNA to report 2Q20 loss of $ 0.35 per share from revenue of $ 27.43 million. The bottom line results beat street analysts by $ 0.04 or 11.43 percent, at the same time, top line results outshined analysts by $ 38.92 million or 141.89 percent.
Stock Performance
Shares of Moderna, Inc. traded low $ -4.93 or -6.98 percent on Wednesday, reaching $ 65.74 with volume of 5.91 million shares. Moderna, Inc. has traded high as $ 69.45 and has cracked $ 65.49 on the downward trend
According to the previous trading day, closing price of $ 65.74, representing a 355.35 % increase from the 52 week low of $ 15.52 and a 25.77 % decrease over the 52 week high of $ 95.21.
The company has a market capital of $ 25.94 billion and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Moderna, Inc. will be hosting a conference call at 8:00 AM eastern time on 29th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.modernatx.com
Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. It has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation.
